Best Options Strategy for XBI
Looking for the best options strategy for SPDR S&P Biotech ETF (XBI)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live XBI option chain right now, and a simple map from your view on XBI to the strategy that fits it. Model any of them in the calculator before you trade.
About XBI
SPDR S&P Biotech ETF (XBI) is an exchange-traded fund (ETF) tracking US biotechnology stocks. Options traders on XBI tend to watch clinical trial and FDA news, M&A activity and interest rates and risk appetite, since these can drive large moves in its price.
XBI for options traders
The SPDR S&P Biotech ETF holds a broad, roughly equal-weighted basket of US biotechnology stocks, which gives it a very different character from a cap-weighted fund. Because so many of its holdings are small and mid-cap drug developers whose value hinges on binary clinical outcomes, XBI behaves like a portfolio of lottery tickets and its implied volatility structurally sits well above the broad market. The catalysts that move it are specific to the sector: clinical trial readouts and FDA decisions, waves of M&A as large pharma buys pipelines, and shifts in interest rates and risk appetite that hit long-duration, cash-burning names hardest. Its options are actively traded, with tight enough markets and good depth across near-term expirations.
That rich, event-driven IV makes XBI a favourite for premium sellers, who lean on iron condors, short strangles, and covered calls to harvest elevated time decay through quieter stretches between catalysts. When a heavy calendar of trial data, an FDA panel, or renewed takeover speculation is expected, traders often turn to long calls, debit spreads, or straddles to position for a sharp directional or volatility move without over-paying. The key caveat is gap risk: because the ETF is a bundle of names that can jump violently on single-stock news or a surprise acquisition, short premium can be tested overnight, and short calls carry assignment risk near dividend or deep in-the-money levels, so position sizing and defined-risk structures matter here.
Today's top-scoring strategy for XBI
Our engine ranks defined-risk strategies on the live XBI chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | CALL | $95 | $9.14 |
| Sell | 2× | CALL | $100 | $6.44 |
| Buy | 1× | CALL | $105 | $4.37 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $125 | −$49 | −$41 | −$37 | −$34 | −$33 |
| $120 | −$37 | −$30 | −$27 | −$26 | −$27 |
| $115 | −$19 | −$16 | −$17 | −$19 | −$22 |
| $110 | $2 | −$3 | −$8 | −$13 | −$17 |
| $105 | $20 | $8 | −$1 | −$9 | −$14 |
| $100 | $26 | $11 | $0 | −$8 | −$14 |
| $95 | $16 | $4 | −$4 | −$11 | −$17 |
| $90 | −$8 | −$11 | −$15 | −$19 | −$22 |
| $85 | −$33 | −$29 | −$28 | −$29 | −$30 |
| $80 | −$51 | −$45 | −$41 | −$39 | −$38 |
| $75 | −$60 | −$56 | −$52 | −$49 | −$47 |
Illustrative example at XBI's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
XBI typically trades with elevated implied volatility, so its options carry richer premiums. Implied volatility drives option prices, so it is worth checking the live chain before you trade.
Dividend and assignment risk
XBI pays a dividend of about 0.3% a year, so short or covered calls on it carry early-assignment risk around each ex-dividend date — in-the-money calls are most exposed just before the stock goes ex-dividend.
Key figures
- 52-week range
- $92.64–$169.89
How to choose an options strategy for XBI
Start with your outlook on XBI, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while XBI stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open XBI in the free calculator →
Frequently asked questions
What is the best options strategy for XBI?
It depends on your outlook. Bullish traders often use a long call or bull call spread on XBI; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are XBI options liquid enough to trade?
SPDR S&P Biotech ETF (XBI) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade XBI options?
Buying a single XBI call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade XBI or any security. Do your own research.
What does SPDR S&P Biotech ETF track?
SPDR S&P Biotech ETF (XBI) is an exchange-traded fund; it tracks US biotechnology stocks. The "About SPDR S&P Biotech ETF" section above explains what it holds and how it works.
Does SPDR S&P Biotech ETF pay a dividend?
Yes — SPDR S&P Biotech ETF currently pays a dividend yielding about 0.3%. If you hold the shares (for example to write a covered call), the ex-dividend date can trigger early assignment, so check it beforehand.
Price trend
Tickers related to XBI
Comparing XBI with similar names can help you choose the best options strategy:
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.